---
title: Single-cell RNA seq-derived signatures define response patterns to atezolizumab
  + bevacizumab in advanced hepatocellular carcinoma
date: '2024-12-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39709141/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241222170843&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Our study unveils two distinct molecular subsets of clinical
  benefit to atezolizumab plus bevacizumab in advanced HCC ("Immune-competent" and
  "Angiogenesis-driven") as well as the main traits of primary resistance to this
  therapy, thus providing a molecular framework to stratify patients based on clinical
  outcome and guiding potential strategies to overcome ...'
disable_comments: true
---
CONCLUSION: Our study unveils two distinct molecular subsets of clinical benefit to atezolizumab plus bevacizumab in advanced HCC ("Immune-competent" and "Angiogenesis-driven") as well as the main traits of primary resistance to this therapy, thus providing a molecular framework to stratify patients based on clinical outcome and guiding potential strategies to overcome ...